Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension.

Robert S BrownMichelle A CollinsSimone I StrasserAmanda EmmettAndrew S ToppMargaret BurroughsRosa FerreiraJordan J Feld

Published in: Infectious diseases and therapy (2022)

G/P treatment for 8 or 12 weeks was equally efficacious in HCV patients with features of PHT. Safety outcomes were similar between PHT and non-PHT groups, with G/P treatment well tolerated across groups. NCTS: NCT03089944, NCT02642432, NCT02738138, NCT02243293, NCT02651194, NCT03235349, NCT02707952, NCT02966795, NCT03069365, NCT03219216.

Keyphrases

blood pressure
hepatitis c virus
type diabetes
human immunodeficiency virus
hiv infected
gestational age
smoking cessation